Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Firibastat in Healthy vs ESRD Subjects
NCT04792333Phase 1Completed
- Sponsor
- Quantum Genomics
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of firibastat in hypertension (HTN) (2 arms), sponsored by Quantum Genomics. Primary endpoint: Firibastat and metabolites (EC33 and QGC515) Concentrations. Started Sep 2019; status: completed.
02
Drugs
firibastat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04792333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792333.